Stephane Bancel - Apr 27, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Apr 27, 2022
Transactions value $
-$2,716,601
Form type
4
Date filed
4/29/2022, 04:18 PM
Previous filing
Apr 22, 2022
Next filing
May 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$77K -549 -0.01% $140.19 5.43M Apr 27, 2022 Direct F1, F2
transaction MRNA Common Stock Sale -$384K -2.72K -0.05% $141.10 5.43M Apr 27, 2022 Direct F1, F3
transaction MRNA Common Stock Sale -$356K -2.5K -0.05% $142.22 5.42M Apr 27, 2022 Direct F1, F4
transaction MRNA Common Stock Sale -$358K -2.5K -0.05% $143.12 5.42M Apr 27, 2022 Direct F1, F5
transaction MRNA Common Stock Sale -$101K -699 -0.01% $143.87 5.42M Apr 27, 2022 Direct F1, F6
transaction MRNA Common Stock Sale -$3.78K -26 0% $145.34 5.42M Apr 27, 2022 Direct F1
transaction MRNA Common Stock Gift -4K -0.07% 5.42M Apr 27, 2022 Direct F7, F8
transaction MRNA Common Stock Sale -$1.44M -10K -0.14% $143.73 6.91M Apr 28, 2022 See Footnote F9, F10
holding MRNA Common Stock 9.05M Apr 27, 2022 See Footnote F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.60 to $140.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.63 to $141.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.64 to $142.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.65 to $143.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.66 to $144.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
F8 The reported disposition represents a bona fide charitable gift made by the reporting person.
F9 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
F10 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F11 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.